PALB2 and cancer: Besides the aforementioned drugs, antibiotic/antineoplastic agents, such as Daunorubicin, Doxorubicin, and Mytomycin C, can also target cancers with DNMT3A (V687F), PALB2 (M723X), and TP53 (R273C) mutations [53,54,55].